New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 15, 2012
07:36 EDTTHLDThreshold Pharmaceuticals reports updated Phase 2 Results for TH-302
Threshold Pharmaceuticals announced updated results from a Phase 2 study of TH-302, the company's investigational hypoxia-targeted drug, in patients with soft tissue sarcoma, including additional results from patients who were administered TH-302 as single agent maintenance therapy following induction with TH-302 in combination with doxorubicin. The results were reported at the 17th annual meeting of the Connective Tissue Oncology Society, or CTOS, taking place Nov. 14-17, in Prague, Czech Republic. Results for Overall Study Population-- Updated results for the 91 patients in the Phase 2 component of the study include: Median progression free survival, or PFS, of 6.7 months. Median overall survival of 21.5 months. One-year survival of 73%, and two-year survival of 44%. Overall best response of 36%. Results for TH-302 Single Agent Maintenance Therapy Population -- Of 91 patients enrolled in the study, 48, or 53%, continued on TH-302 maintenance therapy. The median number of treatment cycles with TH-302 was 4.0. Median PFS was 3.7 months. Median overall survival was 18.0 months. Overall best response (partial and complete responses, unconfirmed) of 54%; five patients who previously had stable disease prior to maintenance achieved a partial response, and one patient who previously had a partial response achieved a complete response.
News For THLD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
15:53 EDTTHLDHigh option volume stocks
11:34 EDTTHLDOptions with increasing call volume; QUNR ASNA CIT THLD K ARO MON BURL SWN
Subscribe for More Information
November 18, 2015
07:01 EDTTHLDThreshold enters into definitive co-promotion agreement with Merck
Threshold Pharmaceuticals (THLD) announced that it finalized a definitive Co-Promotion Agreement for evofosfamide with Merck (MRK) pursuant to the companies' License and Co-Development Agreement entered into on February 2, 2012. Under the terms of the License and Co-Development Agreement, Threshold may co-promote evofosfamide in the U.S. subject to FDA approval of evofosfamide. Evofosfamide is Threshold's investigational hypoxia-activated prodrug, which is currently the subject of two fully enrolled Phase 3 clinical trials in advanced soft tissue sarcoma and advanced pancreatic cancer for which Threshold expects to announce top-line data around the end of 2015. Under the commercial leadership of Merck KGaA, Darmstadt, Germany, the terms of the License and Co-Development Agreement give Threshold the right, at its own cost, to field and be responsible for its own sales force in collaboration with Merck KGaA, Darmstadt, Germany's sales force in the U.S. pursuant to the terms of the new Co-promotion Agreement. Merck KGaA, Darmstadt, Germany remains responsible for all other commercial and medical affairs functions associated with the launch and promotion of evofosfamide. The development milestone payment and royalty payment portions of the License and Co-Commercialization Agreement remain the same. To date Threshold has received upfront and milestone payments of $110 million and can earn additional potential milestone payments of up to $440M.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use